loder

Europe Continuous Bioprocessing Market & Competitive Intelligence, 2019 to 2023, Forecast 2024 to 2031 Research Report

Europe Continuous Bioprocessing Market - By Technology: Continuous Upstream Bioprocessing (Perfusion Bioreactors), Continuous Downstream Bioprocessing (Chromatography, Filtration), Integrated Continuous Biomanufacturing (ICB), Process Analytical Technologies (PAT); By Product Type: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell and Gene Therapy Products; By Country: Germany, United Kingdom, France, Spain, Italy, Russia, Rest of Europe

Report Code
CVMI24072927
Published
July 16, 2024
Last Updated
July 16, 2024
Coverage
Others • Others
Analyst-led, consultative delivery
Enterprise-ready licensing options
Fast turnarounds for custom cuts

Market Snapshot

High-signal KPIs designed for executive scanning.
Indicative snapshot. Request sample for full model outputs.
Market Size (latest)
vs. prior year
CAGR
Forecast window:
Forecast Period
2024–2031
Base years: 2019–2023
Coverage Depth
Segments • Regions • Players

Insights

Consultative narrative + actionable decision support.

1 | Market Overview

The European continuous bioprocessing market involves the adoption of uninterrupted, integrated biomanufacturing technologies for the production of biologics, vaccines, and cell and gene therapies. Unlike traditional batch processing, continuous bioprocessing enables real-time production control, reduces footprint, lowers costs, and accelerates time-to-market for biopharmaceuticals.

Europe’s biologics manufacturing industry is increasingly adopting continuous bioprocessing to enhance efficiency and satisfy the rising demand for monoclonal antibodies (mAbs), recombinant proteins, and personalized medicine. This transition is bolstered by innovations in single-use systems, perfusion bioreactors, continuous chromatography, and process analytics.

 

2 | Market Size and Forecast

Year

Market Value (USD Million)

Notes

2019

490

Driven by perfusion and PAT adoption

2024

770

CAGR 9.5% (2019–2024)

2031

1,780

Projected CAGR 12.4% (2024–2031)

 

3 | Drivers & Challenges

Drivers:

  • Rising demand for efficient, scalable biologics production
  • Regulatory support for continuous manufacturing (EMA, PIC/S)
  • Shift toward personalized therapies and smaller batch sizes
  • Cost, speed, and flexibility benefits over batch processing

 

Challenges:

  • High capital costs for facility retrofitting and technology integration
  • Lack of skilled workforce and process validation expertise
  • Concerns about robustness and process control in multiproduct facilities

 

4 | Segment Insights

By Technology:

  • Continuous Upstream Bioprocessing (Perfusion Bioreactors)
  • Continuous Downstream Bioprocessing (Chromatography, Filtration)
  • Integrated Continuous Biomanufacturing (ICB)
  • Process Analytical Technologies (PAT)

 

By Product Type:

  • Monoclonal Antibodies (mAbs)
  • Recombinant Proteins
  • Vaccines
  • Cell and Gene Therapy Products

 

5 | Regional Insights

  • Germany & Switzerland (38%) – Strong pharma manufacturing and R&D hubs
  • UK & Ireland (XX%) – Biotech innovation and CDMO investments
  • France, Italy & Benelux (XX%) – Biomanufacturing expansion
  • Nordics & CEE (XX%) – Fast-growing biotech and biosimilar clusters

 

6 | Competitive Landscape

Leading players include: Sartorius AG, Merck KGaA, GE Healthcare, Thermo Fisher Scientific, Lonza, Cytiva, MilliporeSigma, Pall Corporation, and Repligen.

Focus areas:

  • Continuous chromatography skids
  • Modular biomanufacturing platforms
  • Bioprocess automation and AI-driven control systems
  • Single-use perfusion systems for mid-scale production
Unlock the executive summary.
Request the sample to review key questions answered.
See what’s included.
Request sample for scope, definitions and segmentation.

Key Players

  • GE Healthcare
  • Sartorius AG
  • Merck KGaA
  • Thermo Fisher Scientific
  • Danaher Corporation
  • Repligen Corporation
  • Eppendorf AG
  • 3M Company
  • Corning Incorporated
  • Getinge AB
  • Bionet
Competitive Dashboard Preview
Shortlist strategic accounts and benchmark positioning.
Loading…
Request Competitive Cut

Segmentation Explorer

Interactively explore markets by segment and geography.
Refine View
Opportunity Index
Directional signals for prioritization and scenario framing.
Interactive
Need a board-ready slide? .
Modeling inputs: analyst assumptions, secondary sources, triangulated validations.

Table Of Contents

Expandable preview of coverage and chapter structure.

 

Europe Continuous Bioprocessing Market Report


 

  1. 1. Europe Continuous Bioprocessing Market Research Report
    1. 1.1 Study Objectives
    2. 1.2 Europe Continuous Bioprocessing Market - Overview
    3. 1.3 Reason to Read This Report
    4. 1.4 Methodology and Forecast Analysis
  2. 2. Europe Continuous Bioprocessing Market Research Report - Preface
    1. 2.1 Europe Continuous Bioprocessing Market Research Report – Detailed Scope and Definitions
      1. 2.1.1 By Technology
      2. 2.1.2 By Product Type
      3. 2.1.3 By Region
  3. 3. Europe Continuous Bioprocessing Market Dynamics
    1. 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers
    2. 3.2. Restraints – By Technology, By Product Type, By Country
    3. 3.3. Opportunities – By Technology, By Product Type, By Country
    4. 3.4. Trends – By Technology, By Product Type, By Country
    5. 3.5. PEST Analysis
    6. 3.6. Porters Five Rule Analysis
    7. 3.7. Company’s Share Analysis (CSA) by Region or By Country
    8. 3.8. Europe Continuous Bioprocessing Market Research Report – DROTs Impact Analysis
    1. 4. Europe Continuous Bioprocessing Market Research Report, Historic Data 2019 - 2023 and Forecast Analysis Data 2024 - 2031
    2. 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 4.2. Annual Market Trend Assessment – Year-on-Year (YoY) Growth Analysis (%)
    4. 4.3. Incremental Market Value/Volume Opportunity between 2019 - 2023 and 2024 - 2031
    5. 4.4. Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
  1. 5. Europe Continuous Bioprocessing Market, By Technology, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 5.1 Continuous Upstream Bioprocessing (Perfusion Bioreactors)
    2. 5.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 5.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 5.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 5.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 5.2 Continuous Downstream Bioprocessing (Chromatography, Filtration)
    7. 5.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 5.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 5.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 5.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    11. 5.3 Integrated Continuous Biomanufacturing (ICB)
    12. 5.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    13. 5.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    14. 5.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    15. 5.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    16. 5.4 Process Analytical Technologies (PAT)
    17. 5.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    18. 5.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    19. 5.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    20. 5.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. Europe Continuous Bioprocessing Market, By Product Type, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 6.1 Monoclonal Antibodies (mAbs)
    2. 6.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 6.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 6.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 6.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 6.2 Recombinant Proteins Vaccines Cell
    7. 6.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 6.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 6.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 6.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    11. 6.3 Gene Therapy Products
    12. 6.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    13. 6.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    14. 6.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    15. 6.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
  1. 7. Europe Continuous Bioprocessing Market Forecast, By Region, 2019 - 2023 and 2024 - 2031 (Market Value, In USD Mn)
    1. 7.1 Europe
      1. 7.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.2 Europe Continuous Bioprocessing Market - Opportunity Analysis Index, By Technology, By Product Type, and Region, 2024 - 2031
  1. 8. Europe Europe Continuous Bioprocessing Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 8.1 By Technology Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.1.1 Continuous Upstream Bioprocessing (Perfusion Bioreactors)
      2. 8.1.2 Continuous Downstream Bioprocessing (Chromatography, Filtration)
      3. 8.1.3 Integrated Continuous Biomanufacturing (ICB)
      4. 8.1.4 Process Analytical Technologies (PAT)
      8.2 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.2.1 Monoclonal Antibodies (mAbs)
      2. 8.2.2 Recombinant Proteins Vaccines Cell
      3. 8.2.3 Gene Therapy Products
      8.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.3.1 Germany
      2. 8.3.2 Uk
      3. 8.3.3 France
      4. 8.3.4 Spain
      5. 8.3.5 Italy
      6. 8.3.6 Russia
      7. 8.3.7 Rest of Europe
    2. 8.4 Europe Europe Continuous Bioprocessing Market – Opportunity Analysis Index, By Technology, By Product Type, and Country, 2024 - 2031
    3. 8.5 Regional Trends Analysis
    4. 8.6 Europe Europe Continuous Bioprocessing Market Research Report - Company Profiles
      1. 8.6.1 Company 1 (Germany)
      2. 8.6.2 Company 2 (Uk)
      3. 8.6.3 Company 3 (Uk)
    9. Competition Landscape
    1. 9.1 Strategic Dashboard of Top Market Players
    2. 9.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
      1. 9.2.1 GE Healthcare
      2. 9.2.2 Sartorius AG
      3. 9.2.3 Merck KGaA
      4. 9.2.4 Thermo Fisher Scientific
      5. 9.2.5 Danaher Corporation
      6. 9.2.6 Repligen Corporation
      7. 9.2.7 Eppendorf AG
      8. 9.2.8 3M Company
      9. 9.2.9 Corning Incorporated
      10. 9.2.10 Getinge AB
      11. 9.2.11 Bionet
  1. 10. Data Collection Method and Research Approach
  2. 11. Principal Presumptions and Acronyms

Methodology & Credibility

Built for enterprise decisions, not vanity metrics.
Triangulated Sizing
Bottom-up, top-down, and peer benchmarks reconciled by analysts.
Primary + Secondary Research
Executive interviews combined with validated public and paid sources.
Scenario & Sensitivity
Base, bull and bear cases to stress-test strategic moves.
Need Confidence Fast?
We’ll map your questions to the report in 15 minutes.
Book A Consultation
Preferred by strategy, marketing, and corporate development teams.

Related Reports

More coverage in adjacent themes and segments.
Ready to move from data to decision?
Get the report, request a sample, or book a consultative briefing.
New chat message received
×

Need help?

Chat with our team in a minute.